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myoD is one of a family of four related basic helix-loop-helix transcription factors involved in the speci®cation and
differentiation of skeletal muscle. We previously identi®ed a 258-bp distal enhancer that is suf®cient for embryonic activa-
tion of myoD and is highly conserved between humans and mice. In this paper, we show using a modi®ed bisul®te
deamination/PCR ampli®cation method that the distal myoD enhancer is completely unmethylated at all the CpG sites
tested in myogenic cells and a subpopulation of somite cells. Conversely, the distal enhancer in nonmuscle cells and
tissues is methylated to an average level of 50% and we ®nd no chromosomes in these tissues with a completely
unmethylated enhancer. We present evidence that demethylation of the distal enhancer in somites of mouse embryos
precedes myoD transcription, suggesting that demethylation of the distal enhancer is an active, regulated process that is
essential for myoD activation. We also show by analysis of transgenic mice carrying a human distal enhancer/reporter
construct in which the three enhancer CpG sites have been mutated that methylation of the distal enhancer is not required
to prevent precocious or ectopic embryonic myoD expression. We propose that a subset of somite cells demethylate the
distal enhancer in response to speci®c developmental signals, thus making the enhancer accessible and able to respond to
subsequent signals to activate the myoD gene. q 1996 Academic Press, Inc.
INTRODUCTION struct that also results in DNA demethylation and conver-
sion of the transfected cells to muscle (Szyf et al., 1992).
Taken together, these experiments suggest that myogenicDNA methylation in vertebrates is associated with a vari-
cell determination can be accomplished by demethylatingety of gene regulatory processes including X-chromosome
the sequences of one or a few regulatory genes.inactivation, genomic imprinting, and transcriptional regu-
myoD is one of four related myogenic regulatory factorslation (reviewed by Bestor et al., 1994; Razin and Kafri,
(MRFs) that control skeletal myogenesis and are ®rst ex-1994; Martienssen and Richards, 1995). Altering the DNA
pressed in somites speci®cally in those cells which willmethylation level of tissue culture cells can have dramatic
give rise to skeletal muscle (reviewed by Buckingham, 1994;effects on cellular phenotypes (Michalowsky and Jones,
Rudnicki and Jaenisch, 1995). myoD and a second MRF1989). 10T1/2 cells treated with 5-azacytidine (an unmeth-
(myf5) together are required to specify and/or maintain cellsylatable analog of cytidine that results in a decrease in the
in the myogenic lineage as mice doubly mutant for theseamount of CpG methylation) convert at high frequency to
two regulatory factors make no distinguishable myoblastsmuscle and at lower frequencies to fat or cartilage pheno-
or muscle (Rudnicki et al., 1993). Establishing how thesetypes (Taylor and Jones, 1982). Konieczny and Emerson
MRFs are developmentally regulated will be fundamentalshowed that this conversion event is clonal and demethyl-
in understanding how somitic cells become determined toation of one or a few loci appears suf®cient for determina-
the skeletal muscle lineage. Jones et al. (1990a) have showntion of 10T1/2 cells to a stably committed muscle lineage
that the myoD gene is expressed and the myoD CpG island(Konieczny and Emerson, 1984). Independent evidence of
demethylated in myogenic cells derived from 10T1/2 cellsthis phenomenon was obtained by transfection of 10T1/2
by 5-azacytidine treatment. However, the CpG island is notcells with an antisense methyltransferase expression con-
methylated in vivo. Thus, while methylation of myoD se-
quences could play a regulatory role in normal embryonic
muscle development, the target must be sequences other1 To whom correspondence should be addressed. Fax: 215-573-
7149. Internet: emersonc@mail.med.upenn.edu. than the myoD promoter.
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tungsten needles and roughly dissected tissues moved into dispase-We have identi®ed a distal enhancer 20 kb upstream of
free PBS for ®nal removal of adherent membranes. Somite and pre-the myoD gene that is suf®cient to recapitulate the entire
somitic mesoderm samples were dissected free of axial structuresprogram of embryonic myoD activation (Goldhamer et al.,
and lateral mesoderm. Presomitic mesoderm samples included all1992, 1995; Faerman et al., 1995). This distal enhancer has
the unsegmented paraxial mesoderm which is the equivalent of 3±some interesting properties that suggest it could be a target
4 somites in length in a 9.5-dpc embryo. Tissue was then placed
for epigenetic regulation. The distal enhancer can direct in 100 ml DNA lysis buffer (see above) containing 0.02 mg/ml plas-
appropriate expression of lacZ reporter constructs in mid DNA carrier and vortexed vigorously. Samples were then pro-
transgenic mice, while those same constructs are expressed cessed as above and resuspended in 20 ml of TE.
promiscuously in tissue culture cell transfection assays
(transient or stable) in nonmuscle cells that do not express
Bisul®te Treatmentthe endogenous myoD gene (Goldhamer et al., 1992, 1995;
Faerman et al., 1995). In addition, the distal enhancer is The bisul®te treatment protocol was modi®ed from Frommer et
al. (1992) and Clark et al. (1994). Ten microliters of DNA (1 mghypersensitive to DNaseI in tissue culture cells (both pri-
including plasmid carrier) was denatured by addition of 0.2 M so-mary cells and established cell lines) that express the myoD
dium hydroxide and incubation at 657C for 10 min, neutralized bygene but is not hypersensitive in cell lines in which the
addition of 0.1 vol 3 M sodium acetate, pH 5.2, and precipitatedgene is not expressed (Goldhamer et al., 1995). These obser-
with 3 vol of ethanol. Alternatively, the DNA was denatured in avations suggest that the distal myoD enhancer is a target
total volume of 12.5 ml in 0.2 M sodium hydroxide for 10 min
for epigenetic regulation that is established in the embryo at 657C and then used directly in the bisul®te reaction without
and, while maintained in tissue culture cells at the endoge- precipitating. DNA was resuspended in 22.5 ml sterile water and
nous myoD locus, is not established de novo in these cells. 77.5 ml 4 M sodium bisul®te, pH 5.0 (0.43 g sodium bisul®te, 0.03
Taken together with 5-azacytidine activation of the myoD g sodium sul®te, 860 ml sterile water, and 10 ml 50 mM hydroxyqui-
gene in 10T1/2 cells, these data suggest that the distal en- none) was added. Samples were mixed, overlaid with mineral oil,
and incubated at 507C in the dark overnight. The sodium bisul®tehancer is a good candidate target for methylation regulation.
was removed by chromatography over a 1-ml Sephadex G50-80In this paper, we show that an unmethylated distal en-
(Sigma) spin column. Forty microliters of 1 M sodium hydroxidehancer correlates with myoD gene expression. Additionally
was then added and the samples incubated at 377C for 30 minwe present evidence showing that the distal enhancer be-
followed by chromatography through a second spin column to re-comes demethylated prior to detectable expression of the
move the base. Samples were stored at 0207C until PCR ampli®ca-
myoD gene in a subpopulation of somite cells that are pre- tion.
sumably in the myogenic lineage. We propose that the
myoD enhancer is demethylated by an active, regulated pro-
PCR Ampli®cation and Quantitation ofcess in response to speci®c developmental signals and,
Methylationwhile demethylation is necessary for myoD expression, ad-
ditional signals are required to activate transcription of the The coding strand relative to the myoD gene of all samples was
myoD gene in somites during embryonic development. PCR ampli®ed for 25 cycles of ampli®cation (947C 1 min, 517C 1.5
min, 747C 1 min) with oligos 632f (GTTTTATAGTATTTGGGG-
GTAT) and 966fc (AAAACCCTAAAACTAACCTTC). The num-
bering in oligo naming is relative to a 1.6-kb RsaI fragment thatMATERIALS AND METHODS
contains the mouse core enhancer (Goldhamer et al., 1995) starting
at base 634. Two microliters of this reaction was then ampli®ed 5
Tissue Culture cycles (947C 1 min, 547C 1.5 min, 747C 1 min) followed by 25
cycles (947C 1 min, 647C 1.5 min, 747C 1 min) with oligos 668fCell lines were obtained from ATCC except 23A2 muscle cells
(GGAATTCGGGGTTTTTTTATAAATTTTTGAGATAGT) and(Konieczny and Emerson, 1984) and IB1 fat cells (I. Akerblom and
939fc (GGTCGACAAAATACTAACCTCTCATACCT). ProductsB. Brunk, unpublished). NB41A3 and BNL cells were grown in 90%
were gel puri®ed using the GeneClean kit (Bio101). Ten percentDMEM/10% FBS, C2C12 cells in 85% DMEM/15% FBS, 10T1/2
of the puri®ed band was sequenced by thermal cycle sequencingand IB1 cells in 90% BME/10% FBS, and 23A2 cells in 85% BME/
(Circumvent, New England Biolabs) using primer 668f and electro-15% FBS. Proliferating cell cultures were harvested for DNA by
phoresed on an 85-cm sequencing gel to facilitate band separation.scraping in DNA lysis buffer (150 mM NaCl, 2% SDS, 15 mM
Dried gels were exposed for 4 hr to overnight on a phosphorimagerEDTA, 400 mg/ml Proteinase K (Merck), 50 mM Tris±HCl, pH 7.5)
(Fuji Bas1000 or Molecular Dynamics 445si). Band intensities wereand incubated for 2 hr at 557C or overnight at 377C. Samples were
quantitated using either MacBas (Fuji) or IPLabGel (Signal Analyt-then extracted with phenol, phenol/chloroform, ethanol precipi-
ics) software and the data analyzed and graphed using Microsofttated, and resuspended in TE.
Excel. Averages for all samples are from at least three independent
experiments and error bars represent one standard deviation above
and below the mean.Embryo Dissections and DNA Isolation
Embryos were derived from ICR (Fox Chase Cancer Center) or Subcloning and Sequencing PCR Products
CD-1 (Charles River) mice. Noon of the day of the vaginal plug
was considered 0.5 dpc. Embryos were dissected in PBS with or PCR products were phenol/chloroform extracted and precipitated
then digested with EcoRI and SalI, gel puri®ed using GeneCleanwithout 10% dispase (Boehringer-Mannheim) using sharpened
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(Bio 101), and ligated into a SalI/EcoRI-digested bluescript (KSII/) al., 1991) also termed the proximal regulatory region (PRR)
vector (Stratagene). Subcloned plasmid DNA was prepared using (Tapscott et al., 1992) and an enhancer approximately 5 kb
the Wizard kit (Promega) and sequenced using sequenase 2.0 (USB) upstream named the distal regulatory region (DRR) (Taps-
and standard protocols. cott et al., 1992). These more proximal elements together
recapitulate part of the developmental program of myoD
expression including autoregulation (Tapscott et al., 1992;Genomic Southern Methylation Analysis
Zingg et al., 1994), ®ber type-speci®c expression (Hughes
Twenty micrograms of genomic DNA was digested to comple- et al., 1993), and some aspects of embryonic expression
tion with RsaI and HpaII or MspI, phenol/chloroform extracted, (Asakura et al., 1995). We localized the distal enhancer to
precipitated, and electrophoresed in a 1% agarose gel. The DNA a 258-bp core sequence that is highly conserved in mice
was transferred to a nytran membrane (Schleicher & Schuell) via (Goldhamer et al., 1995) and also is located distally 20 kb
vacublotting (Hoeffer) and cross-linked in a stratalinker (Stratagene) upstream of the mouse myoD gene (Fig. 1A). There are six
following manufacturers' recommendations. The ®lter was hybrid-
CpG sites in the mouse core enhancer (Fig. 1B) that lie inized following the protocol of Church and Gilbert (1984) with a 32P-
regions of the enhancer where proteins interact as shownlabeled 1.6-kb RsaI fragment containing the mouse core enhancer.
both by in vitro footprinting assays (Goldhamer et al., 1995)
and by gel electromobility shift analysis (unpublished data).
Three of these sites (CpG 2, 4, and 5) are conserved in theMutagenesis
human enhancer. We used the bisul®te deamination
CpG mutations were created by the PCR-based overlap extension method (Frommer et al., 1992; Clark et al., 1994) to deter-
method as previously described (Ho et al., 1989), using Vent poly-
mine the methylation status of each of the conserved sitesmerase, and the core enhancer cloned in pBluescript (KS/) as the
in DNA isolated from mouse tissue culture cell lines, neo-template (Goldhamer et al., 1995). By using mutant derivatives as
nates, and embryos.the template for subsequent rounds of mutagenesis, a construct
was obtained in which all three CpG dinucleotides were mutated
to TpG. Mutations were con®rmed by sequencing both strands of
The Bisul®te Method Is a Reliable Assay for Site-the core enhancer.
Speci®c DNA Methylation
We examined whether the bisul®te deamination method
Transgenic Mice combined with phosphorimager quantitation provides a
consistent and accurate measure of the methylation stateThe CpG mutant construct 258(CpG1-3)/-2.5lacZ was made by
of speci®c CpG residues. Incubation of DNA in sodiumexcising the mutagenized core enhancer from pBluescript (KS/)
bisul®te at low pH followed by a high pH incubation resultswith SalI and XbaI and cloning the fragment upstream of the myoD
promoter in the lacZ construct -2.5lacZ (Goldhamer et al., 1995) in deamination of cytosine to uracil. Methylated cytosines
utilizing unique SalI and SpeI sites. The myoD mutant enhancer/ are protected from this deamination reaction. Thus, follow-
promoter lacZ fusion was liberated from vector sequences and frag- ing PCR ampli®cation of bisul®te-treated DNA and subse-
ments puri®ed as previously described (Goldhamer et al., 1992). quent cycle sequencing of the product, the intensity of the
Transgenic mice were produced by pronuclear injection of B6/D2 bands on a sequencing gel in the C lane relative to the T
F1 hybrid one cell stage embryos by the Cancer Center Transgenic
lane quanti®es the level of methylation at any C residueFacility of the University of Pennsylvania Medical School. Three
subject to methylation. In order to determine by indepen-founder mice were identi®ed by slot-blot analysis of tail DNA using
dent means the methylation levels of the C2C12 anda probe speci®c to lacZ sequences. Stable transgenic lines were
NB41A3 DNAs that we used in the control experiment, weproduced by mating founder mice to B6/D2 F1 hybrid mice. For
performed a genomic Southern analysis using the methyla-embryo analysis, transgenic mice were mated to either B6/D2 F1
hybrid mice or FVB/N mice with similar results. Histochemical tion-sensitive enzyme HpaII and its isoschizomer MspI,
staining for b-galactosidase was done as previously described (Gold- which cut at CpG 6 and at a second site outside the core
hamer et al., 1992). enhancer. HpaII digested the C2C12 DNA to completion
and the NB41A3 DNA only slightly (Fig. 2B), demonstrating
that these two HpaII sites are unmethylated in C2C12 DNA
RESULTS and greater than 90% methylated in NB41A3 DNA. We
then conducted a mixing experiment using C2C12 DNA
and NB41A3 DNA. As an internal control for the bisul®teThree regulatory regions that have been identi®ed up-
stream of the myoD gene are depicted in Fig. 1A. We identi- deamination and subsequent sequencing reactions, the
DNA was methylated to completion in vitro with AluI®ed a distal enhancer located 20 kb upstream of the human
gene that is suf®cient for embryonic activation of myoD in methylase prior to the bisul®te treatment. Figure 2A shows
the raw data from this mixing experiment. In the 0%all muscle forming regions of the embryo (Goldhamer et
al., 1992, 1995; Faerman et al., 1995) recapitulating myoD NB41A3 DNA sample, there are very faint if any signals in
the C lane and correspondingly strong signals in the T lane,embryonic expression as determined by in situ hybridiza-
tion analyses. Two additional regulatory elements have indicating a very low level of methylation. The exceptions
are the control AluI-methylated residues which have abeen identi®ed in mouse sequences; the promoter (Zingg et
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FIG. 1. Structure of the myoD gene and sequence of the distal enhancer. (A) The myoD gene structure derived from restriction mapping
a cosmid clone and published sequence (Zingg et al., 1991). The distal regulatory region (DRR) and proximal regulatory region (PRR) were
identi®ed by Tapscott et al. (1992) and Zingg et al. (1991). (B) The sequence of the mouse distal core enhancer which begins at base 634
relative to the beginning of the 1.6-kb RsaI fragment containing the enhancer. The bisul®te-treated forward strand is shown aligned with
the mouse sequence. All CpG dinucleotides are marked with a box and those that are conserved between mice and humans are indicated
in bold. The three CpG sites that are the focus of this analysis are indicated by underlining.
strong C signal and a weak T signal. In contrast, in the and 5. In this study, therefore, we have limited our analysis
to the conserved CpG sites 2, 4, and 5 unless otherwise100% NB41A3 DNA sample, there are strong signals in the
C lane and relatively weak signals in the T lane, indicating noted. In Fig. 2D, the data are presented as a bar graph for
each sample showing the percent C of CpG sites 2, 4, andextensive methylation of the ®ve CpG sites visible on the
gel. CpG 1 migrates far ahead of the other ®ve sites and 5 and the average of these three sites to provide an overall
value re¯ecting the relative level of myoD enhancer meth-was not included in our analysis.
Figures 2C and 2D show the corresponding graphs using ylation.
To verify the accuracy of the phosphorimager quantita-the phosphorimager quantitated data from the control gel
shown in Fig. 2A. In Fig. 2C, the data are graphed to show tion, we sequenced subcloned products of PCR ampli®ca-
tions and found that the percent C was consistent with thethe relationship between the percent NB41A3 DNA in the
sample and the percent C as calculated from the gel. Values percent C as determined by phosphorimager quantitation
(Table 1). These data together demonstrate the ef®cacy offor sites 2, 4, and 5 are similar and, more importantly, follow
the linear increase of NB41A3 DNA, demonstrating the va- using bisul®te deamination and phosphorimager quantita-
tion to detect differences in the CpG methylation level be-lidity of the bisul®te reaction and phosphorimager quantita-
tion for comparing relative methylation levels between tween DNA samples, providing the means to quantitate the
methylation state of the myoD distal enhancer not only insamples for these three sites. In contrast, sites 3 and 6 devi-
ate from this linear relationship and even at 0% methylated cell lines but also in somites of the developing embryo.
DNA, where there are no methylated CpG residues in the
enhancer, there is a wide disparity between the percent C The myoD Enhancer Is Unmethylated in Muscleof CpG sites 3 and 6 compared to sites 2, 4, and 5. The
Cells in Culturevariation in the phosphorimager data seems to be due to
higher general background labeling in the region of the se- We ®rst tested the CpG methylation status of the distal
myoD enhancer in established cell lines. Myogenic C2C12quencing gels where sites 3 and 6 migrate. This particular
gel shows lower background than many. Thus, the values cells, which express the myoD gene at high levels (Tapscott
et al., 1988), show a very low level of enhancer methylationfor sites 3 and 6 can not be reliably quantitated using the
phosphorimager. We have no evidence that the methylation (average for the three CpG sites of 8% C, Fig. 3A). In con-
trast, the myoD enhancer in nonmuscle cell lines, whichlevels of sites 3 and 6 differ substantially from sites 2, 4,
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FIG. 2. Control gel establishing the ef®cacy of phosphorimager quantitation of CpG methylation. (A) An example of a gel from the
methylation analysis. This gel is a mixing experiment using unmethylated DNA from C2C12 muscle cells and heavily methylated DNA
from NB41A3 neuroblastoma cells. The two AluI sites were used as internal controls for some experiments including the one shown
here. (B) An independent veri®cation using standard HpaII and MspI digests showing that C2C12 DNA is unmethylated and NB41A3
DNA is heavily methylated. All samples were digested with RsaI to give a 1.6-kb band. HpaII and MspI cut within this band at base 858,
which is CpG site 6, and an additional CpG outside the core enhancer 53 bp closer to the myoD gene to yield two bands of 858 and 693
bp. (C and D) The data generated from quantitating the gel in A using a phosphorimager and plotting the values using Microsoft Excel.
In C the value for the % C (C signal divided by the C plus T signal) for each CpG 2±6 is plotted versus the percent methylated NB41A3
DNA in the sample. (D) The data as they will be presented in the rest of this paper. The average is the average % C of sites 2, 4, and 5
and thus represents the average methylation of the enhancer for any particular sample.
do not express the myoD gene, shows much higher levels C2C12 and none for BNL were completely unmethylated
(Table 1). Thus, there is a positive correlation between anof methylation (57% C for BNL liver cells and 82% C for
NB41A3 neuroblastoma cells). We subcloned and sequenced unmethylated myoD distal enhancer and expression of
myoD in these cell lines.®ve PCR products representing individual chromosomes for
BNL cells and six for C2C12 cells and all subclones for We also tested myoD enhancer methylation in muscle
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TABLE 1 shows a low level of enhancer methylation (17% C) com-
Average Percentage of Cytosine Residues at CpG Sites 2, 4, and pared to DNA isolated from nonmuscle tissue (liver, 60%
5 Determined by Subcloning and Sequencing PCR Products C; heart, 48% C; and brain, 52% C). The low level of meth-
Representing Individual Chromosomes Compared to the Data ylation in the muscle samples is likely due to contamina-
from Phosphorimager Quantitation tion of these samples with methylated supporting struc-
tures such as connective tissue. Thus, it appears that the% C from % C from % Unmethylated
myoD distal enhancer is unmethylated in muscle tissuesCell line phosphorimager subcloning chromosomes
in newborn pups, while the nonmuscle tissues we tested
10T1/2 ®broblasts 58% { 4%* 53% 0% (0/5) show a methylation level of 48±60% C, demonstrating a
23A2 myoblasts 12% { 6% 7% 80% (4/5)
correlation between demethylation of the myoD enhancerBNL liver cells 57% { 5% 60% 0% (0/5)
and myogenesis in vivo. Thus, the enhancer is in a demethy-C2C12 myoblasts 8% { 4% 0% 100% (6/6)
lated state in muscles both in vivo and in myogenic tissue
Note. Column three shows the percentage of subclones that were culture cells.
completely unmethylated. It has been reported that a MLC1-CAT transgene shows
* Standard deviation is from four experiments. a gradient of methylation along the anterior/posterior axis
in transgenic mice (Donoghue et al., 1992; Grieshammer et
al., 1995), suggesting the existence of a system for methylat-
ing regulatory sequences in muscle in a graded fashion. We
and fat cell lines derived from 10T1/2 ®broblast cells by do not detect differences in the methylation level of the
treatment with 5-azacytidine (an unmethylatable analog of endogenous myoD enhancer in hindlimb and forelimb mus-
cytidine that blocks DNA methylation). The enhancer in cle of newborn mice. This suggests that the mechanism
10T1/2 cells and IB1 cells (a 5-azacytidine-derived fat cell regulating endogenous myoD enhancer methylation levels
line) shows a high level of methylation (Fig. 3B). The level must differ from the mechanism regulating differential
of myoD enhancer methylation in IB1 cells appears to be methylation of the MLC1-CAT transgene in muscles along
slightly reduced relative to 10T1/2 cells, perhaps re¯ecting the A/P axis.
a general 5-azacytidine-induced decrease in methyltransfer-
ase activity; however, enhancer methylation is dramatically
decreased in 23A2 cells, a 5-azacytidine-derived muscle line The myoD Distal Enhancer Becomes Demethylated
in Somites during Embryonic Development(Konieczny and Emerson, 1984) that expresses the myoD
gene at a high level (Konieczny et al., 1989). The average To determine the CpG methylation level of the en-
level of myoD enhancer methylation in 23A2 muscle cells hancer in relation to embryonic activation of the myoD
is 12% C compared to 58% C in the parental 10T1/2 cell gene, we ®rst examined the enhancer methylation status
line and 48% C in the IB1 fat cell line (Fig. 3B). We sub- in somites and nonmuscle tissues of 11.5-day embryos
cloned and sequenced ®ve PCR products representing indi- when the myoD gene is expressed at high levels in sub-
vidual chromosomes for 10T1/2 and 23A2 DNA and 80% populations of somite cells (Sassoon et al., 1989; Gold-
of 23A2 and 0% of 10T1/2 subclones are entirely unmethyl- hamer et al., 1992; Faerman et al., 1995). Somites develop
ated (Table 1). 10T1/2 cells and their derivatives are hypo- in an anterior to posterior progression with new somites
tetraploid; thus, as many as four copies of the myoD gene condensing from the paraxial mesoderm every 2±2.5 hr
could be present in 23A2 cells. We expect that the myoD (Rugh, 1968). Thus, the timing of regulatory events dur-
gene is only expressed from those chromosomes (likely ing somitogenesis can easily be assessed as the embryo
three of the potential four) that have an unmethylated distal contains somites representing a broad spectrum of devel-
enhancer; however, we cannot test this hypothesis. These opmental ages. Again, we observe a positive correlation
data establish a strong correlation between an unmethyl- between decreased enhancer methylation and myogen-
ated myoD enhancer and expression of the myoD gene, sug- esis (Fig. 4A). The highest levels of enhancer methylation
gesting that myoD enhancer demethylation by 5-azacyti- are observed in the presomitic mesoderm (65% C) and
dine treatment is pivotal for the determination of 10T1/2 the neural tube (73% C). In contrast, somites, including
cells to the myogenic lineage. the three most newly formed somites, show lower levels
of methylation (35±42% C). These data indicate that the
enhancer becomes demethylated in 11.5-dpc embryosThe myoD Distal Enhancer Is Unmethylated in
less than 6 hr following condensation of the presomiticMuscles of Newborn Mice
mesoderm to form somites. The forelimb bud, which ex-
presses myoD in some cells, and the heart, which doesThe methylation status of the myoD distal enhancer in
muscle and nonmuscle tissues of newborn mice was exam- not express myoD, show intermediate levels of methyla-
tion (52±56% C). These percentages represent the aver-ined to establish in vivo relevance for the tissue culture
data. We found that the level of enhancer methylation is age enhancer methylation for all cells in a particular sam-
ple. Data presented below show that the enhancer be-much lower in muscle tissue compared to nonmuscle tissue
(Fig. 3C). DNA isolated from forelimb or hindlimb muscle comes demethylated in a subpopulation of somite cells
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(presumably myogenic), while the majority of cells main-
tain a high level of enhancer methylation.
In order to determine more precisely the develop-
mental timing of myoD enhancer demethylation, we ex-
amined the enhancer methylation status in somites at
different positions along the anterior-posterior axis of
four 9.5-dpc (23±26 somites) embryos (Fig. 4B). The
methylation level of the enhancer in the presomitic
mesoderm is 74% C and does not decrease signi®cantly
in somites 1± 2 or somites 5±6. However, in somites 10±
11, the enhancer methylation level is decreased to 50%
C and remains at that level in more anterior somites.
While the standard deviations for some samples from
these embryos is high, somites 10±11 and somites lo-
cated more anterior in each individual embryo show a
reproducible decrease in enhancer methylation compared
to presomitic mesoderm. As an additional test of the
quantitation, we subcloned and sequenced PCR products
representing individual chromosomes from a 9.75-dpc
embryo (see below) and con®rmed that the enhancer be-
comes demethylated by somite 10. These data indicate
that the distal enhancer becomes demethylated during
somitic development in 9.5-dpc mouse embryos between
somite 6 and somite 10.
In order to distinguish whether a subpopulation of cells
becomes demethylated in somites showing decreased en-
hancer methylation or, alternatively, the methylation
level decreases for all cells, we subcloned and sequenced
PCR products representing individual chromosomes
from a 9.75-day (27-somite) embryo. We were able to ana-
lyze ®ve of the CpG sites in the core enhancer in this
analysis (sites 2 ±6) as we simply scored for the presence
of a C versus a T without the need for phosphorimager
quantitation. The presomitic mesoderm and somites 5±
6 are heavily methylated (78± 80% C) and none of the 37
sequenced subclones representing individual chromo-
somes from these two tissues were entirely unmethyl-
ated at all ®ve of the sites in the core enhancer (Table 2).
As seen using phosphorimager quantitation, somites 9±
10 and somites 13±14 show decreased enhancer methyla-
FIG. 3. myoD enhancer methylation is absent in myogenic tissue
culture cell lines and decreased in muscles from newborn pups. (A)
A comparison of the BNL liver cell line, the NB41A3 neuro-
blastoma cell line, and the C2C12 myoblast cell line. (B) A compari-
son of three cell lines, two of which were derived from the parental
10T1/2 ®broblast cell line by treatment with 5-azacytidine. 23A2
is a 5-azacytidine-derived muscle cell line (Konieczny and Emerson,
1984) and IB1 is a 5-azacytidine-derived fat cell line. All DNA sam-
ples were isolated from proliferating cells; however, we did not
detect any differences in methylation patterns when DNA was
isolated from con¯uent, differentiated cells (data not shown). (C)
Data from tissues dissected from newborn pups. FL, forelimb mus-
cle; HL, hindlimb muscle. Error bars indicate one standard devia-
tion above and below the mean for at least three and in most cases
four experiments.
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FIG. 4. The myoD distal enhancer becomes demethylated in somites of mouse embryos. (A) The data from three 11.5-day embryos. Psm,
unsegmented presomitic mesoderm; Som1-3, the newest three somites to segment from the presomitic mesoderm; Som@HLB, three
somites from the level of the hindlimb bud; Som@FLB, three somites from the level of the forelimb bud; Ant Som, the three most anterior
somites; FLB, forelimb bud; N.T., neural tube from the level of the forelimb bud. (B) Data from four 9.5-day embryos. Somites are numbered
from the most newly formed somite, i.e., Som1,2 indicates the two most newly formed somites.
tion levels to about 50% C. Signi®cantly, this decrease subclones for somites 13±14). The methylation level of
subclones which contain at least one methylated site (Ta-in methylation can be accounted for almost entirely by
the presence of subclones representing chromosomes ble 2, column 3) does not decrease signi®cantly during
somite development. These data show that the myoDthat are completely unmethylated at all ®ve of the CpG
sites (15% of subclones for somites 9 ±10 and 37% of distal enhancer is heavily methylated in the presomitic
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TABLE 2
Average %C of CpG Sites 2±6 as Determined by Subcloning and
Sequencing Individual PCR Products
% C at CpG % Unmethylated % C of methylated
Tissue sites 2± 6 chromosomes chromosomes
Presomitic mesoderm 80% 0% (0/18)a 80%
Somites 5± 6 78% 0% (0/19) 78%
Somites 9± 10 54% 15% (3/20) 64%
Somites 13±14 45% 37% (7/19) 72%
Note. Tissue was dissected from a 9.75-dpc (27-somite) embryo.
Somites are numbered with 1 being the most posterior. The de-
crease in % C of the enhancer in somites 9±10 and somites 13±
14 can be accounted for by those chromosomes that are entirely
unmethylated at these ®ve CpG sites as the % C for those chromo-
somes which retain at least one methylated CpG at these sites
remains relatively constant (column 3).
a The number of subclones analyzed is indicated in the paren-
theses.
mesoderm and somites 5 ±6 of 9.75-dpc mouse embryos
and becomes completely demethylated between somite
6 and somite 10 in chromosomes of a subpopulation of
somite cells as myogenesis progresses during somite mat-
uration.
Methylation of the Distal Enhancer Is Not
Required to Prevent Precocious or Ectopic
Embryonic Expression of myoD
We tested whether the timing or skeletal muscle restriction
of embryonic myoD expression is regulated by CpG methyla-
tion of the distal enhancer. The three CpG sites in the 258-
bp human enhancer, all of which are conserved with the
mouse myoD enhancer, were mutated to TpG, ligated to a
human myoD promoter/lacZ reporter, and injected into mice.
Three independent stable transgenic lines were generated and
analyzed. There is variability in the level of expression in the
three lines, probably due to site of integration effects; however,
even the high expressing line does not show premature expres-
sion in muscle forming regions of whole mount (Fig. 5) or
sectioned (data not shown) embryos. This is evidenced in the
11.5-day embryos in Fig. 5 as the posterior extent of expression
in both the ventral and dorsal somite is the same for the
wildtype embryo in Fig. 5A and the highly expressing mutant
embryo in Fig. 5B. The highly expressing line does show ec- FIG. 5. 11.5-dpc transgenic mice carrying a CpG mutant, human
distal enhancer reporter construct do not show precocious or ectopictopic expression in the neural tube and forebrain and broad-
transgene expression. (A) An embryo carrying the wildtype humanened expression in ¯ank somites; however, as the other two
258/-2.5LacZ enhancer construct. (B and C) Two lines carrying a CpGlines do not show similar expression patterns, it is likely that
mutant enhancer construct which gives expression patterns similarthe aberrant expression observed in the highly expressing line
to the wildtype construct. B is a line that expresses very strongly andis caused by site of integration effects. All three lines show
C is a line that expresses weakly. The embryo in B shows ectopicspeci®c loss of expression in the anterior muscle masses of
staining in the forebrain, neural tube, and broadened expression in
the forelimb buds (indicated by the arrows in Fig. 5). This loss ¯ank somites. As the other two lines do not show similar staining
of expression is likely due to an alteration in DNA/protein (compare with C), there is no consistent misexpression that can be
interactions caused by mutation of CpG 2 as a linker±scanner attributed to loss of methylation. The loss of transgene expression
mutation of this region shows a speci®c limb phenotype simi- in the developing limb is indicated by an arrow.
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FIG. 6. Diagrammatic representation summarizing myoD gene expression/transgene expression, myoD protein staining, and somite
methylation analysis data. The myoD enhancer/lacZ transgene staining patterns correlate well with the in situ data (Faerman et al., 1995)
(Sassoon et al., 1989), so for the purposes of this ®gure, we only present the transgene data (Goldhamer et al., 1992, 1995; Faerman et al.,
1995), indicated in blue. The protein staining pattern in the 9.5-dpc embryo (Smith et al., 1994) is striped and the somites in which we
detect demethylation relative to the presomitic mesoderm are shown outlined in red. MyoD protein staining data were not presented for
11.5-dpc embryos although 10.5-dpc embryos show staining in the fourth somite from the presomitic mesoderm (Smith et al., 1994). The
resolution of this representation is at the level of the entire somite. We are not attempting to distinguish subsomitic localization of
expression. A somite is marked as positive if it contains a positive signal anywhere within it. Thus, at a cellular level, the differences in
enhancer demethylation and MyoD protein staining are much more striking, as we see 15% of enhancer subclones representing individual
chromosomes from somites 9±10 are unmethylated and Smith et al. (1994) report only one or two MyoD-positive cells in somite 11.
lar to the CpG mutant mice (unpublished observations). Addi- data suggest that methylation of the enhancer is not required
to restrict the domain of expression or timing of activation oftionally, CpG 2 is in a region of the enhancer that contains a
predicted AP-1 site and is protected from DNAseI digestion the human myoD enhancer transgene during early em-
bryogenesis.in in vitro footprinting assays (Goldhamer et al., 1995). These
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bly detect enhancer demethylation in somites 9±10 num-DISCUSSION
bered from the presomitic mesoderm. MyoD protein is ®rst
detected in some 9.5-day embryos in somites 11±12 in oneDemethylation of the Distal Enhancer Correlates
or a few cells per somite (depicted in Fig. 6) (Smith et al.,with myoD Gene Expression
1994). In the lacZ staining and in situ hybridization analy-
We previously identi®ed a distal enhancer 20 kb upstream ses, myoD expression is ®rst detected later in 10.0- to 10.5-
of the myoD gene that is suf®cient to recapitulate all as- dpc, 30/-somite embryos. RT±PCR experiments on 9.5-dpc
pects of embryonic myoD activation. This enhancer has whole embryos detect very small amounts (1% maximal
properties suggesting that it is regulated in part by epige- expression) of myoD message (Hannon et al., 1992), indicat-
netic means (Goldhamer et al., 1992). In this paper, we show ing that the myoD gene is transcribed at a very low level
that this distal myoD enhancer is methylated in nonmuscle in 9.5-dpc embryos but providing no information as to the
embryonic tissues and cells in culture. However, in muscle localization of expression. To detect a change in enhancer
cells in culture and in subpopulations of somite cells, the methylation level in the total somite requires an abundance
core enhancer becomes completely demethylated at all ®ve of cells that have demethylated the enhancer as the majority
of the CpG sites we tested, providing evidence that demeth- of cells retain a high level of enhancer methylation. We ®nd
ylation of the distal enhancer is an important component that 15% of enhancer subclones from somites 9±10 and
of myoD gene regulation during myogenesis. We propose 37% of subclones from somites 13±14 are completely un-
that complete demethylation of the myoD enhancer is re- methylated in a 9.75-dpc embryo (Table 2). This represents
quired for myoD expression, both in cell culture and during a much greater number of cells than are initially myoD
embryogenesis in the mouse. positive as detected by antibody staining or later by lacZ
Unlike the distal enhancer, the methylation state of other staining of transgenic mice (see for example Fig. 5A). Thus,
regulatory regions of the myoD gene does not correlate with it is likely that the population of cells that are demethylated
myoD expression. The myoD promoter is unmethylated in in these somites is much larger than the population of cells
both muscle and nonmuscle tissues in 11.5-dpc embryos that initially activate myoD, providing additional evidence
(data not shown), in adult mice (Jones et al., 1990b), and in that enhancer demethylation precedes myoD expression at
tissue culture cell lines (data not shown; Rideout et al., the cellular level during somite development in 9.5-dpc em-
1994). The lack of methylation of the myoD promoter in bryos and suggesting that transcriptional activation does
nonmuscle cells is likely because the promoter borders a not immediately follow enhancer demethylation. While we
CpG island. CpG islands have been shown to be protected cannot determine from our analyses which cells in the so-
from methylation during normal development unless they mite undergo demethylation of the enhancer, we hypothe-
are on the inactive X chromosome (reviewed by Bird, 1986). size, based upon the timing and pattern of activation of
We have also examined the CpG methylation level of the myoD expression, that demethylation is occurring in cells
distal regulatory region (DRR) identi®ed by Tapscott et al. of the dermamyotome that are migrating into the myotome
(1992) in cell lines and ®nd a variable but low amount and cells of the myotome itself. We estimate that the per-
(20% C) of methylation of this regulatory sequence; how- centage of somite cells in these populations is similar to
ever, the level of methylation does not correlate with ex- the percent of unmethylated chromosomes that we ®nd in
pression of myoD as parental 10T1/2 ®broblast cells show somite samples.
a lower level of DRR methylation than do 5-azacytidine- Grieshammer et al. (1995) have shown that demethyl-
induced 23A2 myogenic cells (data not shown). Thus, of the ation of the MLC1 enhancer sequences in a MLC1-CAT
identi®ed myoD regulatory regions, the methylation state transgene is detectable at approximately somite 20 from
of the distal enhancer alone correlates with myoD gene the presomitic mesoderm in 11.5-dpc mice. They detect
expression and myogenesis. expression of the reporter construct in more posterior so-
mites that have not yet demethylated the enhancer, leading
to their conclusion that demethylation of these sequencesDemethylation of the myoD Distal Enhancer
is a consequence resulting from transcription of the CATPrecedes Detectable Expression of myoD in
reporter construct. In contrast, we observe demethylationEmbryos
of the myoD distal enhancer in the most posterior three
somites of 11.5-day embryos (depicted in Fig. 6), well beforeComparison of the methylation data with published work
reporting myoD expression patterns suggests that the en- expression of the myoD gene is detected by lacZ staining
of transgenic embryos (Goldhamer et al., 1992, 1995; Faer-hancer becomes demethylated prior to myoD transcription.
Figure 6 shows the methylation data compared with the man et al., 1995). Thus, distal enhancer demethylation pre-
cedes myoD expression at both embryonic stages that wepublished gene expression data as determined by in situ
hybridization studies (Faerman et al., 1995; Sassoon et al., have analyzed. This is consistent with our ®nding that a
mutagenized reporter construct with no CpG sites in the1989), by lacZ staining of myoD enhancer/reporter
transgenic mice (Goldhamer et al., 1992, 1995; Faerman et distal enhancer is expressed in transgenic mice with a wild-
type pattern of activation in somites during embryogenesis.al., 1995), and by antibody staining against the MyoD pro-
tein (Smith et al., 1994). In 9.5-dpc embryos, we reproduci- These data together with the ®nding that all cells that ex-
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press myoD have an unmethylated enhancer suggest that methylation level of the MLC1 enhancer and must be the
result of maintenance methylation because methylation can-demethylation of the enhancer is necessary but not suf®-
cient for myoD expression. not be extablished de novo on these same MLC1-CAT con-
structs directly transfected into these lines. The data pre-
sented in this paper showing that demethylation precedes
The Role of Distal Enhancer Methylation in the myoD expression and all myoD expressing cells have a de-
Developmental Regulation of the myoD Gene methylated enhancer demonstrate the importance of en-
hancer demethylation for expression and are consistent withOur ®ndings establish that the myoD distal enhancer is
a target of methylation regulation based on our develop- a repressive regulatory role for enhancer methylation. We do
not see aberrant expression of the mutated CpG enhancermental data showing demethylation of the enhancer pre-
cedes myoD expression and transgenic data showing the transgene in older embryos (data not shown); however, both
wildtype and mutant enhancer reporters show diminisheddistal enhancer is suf®cient for correct embryonic activa-
tion in transgenic mice (Goldhamer et al., 1992, 1995; Faer- expression later in development and undetectable transgene
expression in neonates and, as discussed previously, methyla-man et al., 1995). The CpG mutant transgene also is acti-
vated correctly, showing that methylation of the three CpG tion of other regions of the construct could be suf®cient to
repress transcription in nonmuscle tissues. We can addresssites in the human enhancer is not essential for myoD re-
pression or activation during early embryogenesis; however, the repressive role of enhancer methylation directly by meth-
ylating the enhancer in vitro and testing the effects of en-it is possible that distal myoD enhancer sequences can di-
rect the appropriate methylation of other myoD gene se- hancer methylation on activity using tissue culture transfec-
tion assays.quences that are critical for myoD activation or repression
in nonmyogenic cells. For instance, the distal enhancer
could also direct demethylation of CpG sites ¯anking the Developmental Control of myoD Distal Enhancerenhancer to open chromatin making regulatory sequences
Demethylationin the enhancer or promoter accessible to transcription fac-
tors. In this case, we would expect to identify additional Demethylation of the distal enhancer prior to expression
of the gene suggests that myoD enhancer demethylationsequences that undergo demethylation dependent on the
presence of the enhancer. is a discreet, regulated event that is separable from myoD
transcription. Furthermore, myoD expression does not im-Alternatively, enhancer methylation may play a repressive
regulatory role later in development to ensure that the myoD mediately follow demethylation, suggesting that, while de-
methylation of the enhancer is necessary, it is not suf®cientgene remains silent in differentiated nonmuscle tissues. Such
repression would be critical for a gene such as myoD that has and additional signals/factors are required for myoD activa-
tion. Consistent with this interpretation, transgenic micedominant regulatory activity to convert cells to the muscle
phenotype (Davis et al., 1987; Weintraub et al., 1989). Evi- that carry a mutated human distal enhancer that does not
contain any CpG sites and thus can not be methylated dodence for this hypothesis comes from the observation that
reporter constructs containing the distal human myoD en- not show precocious or ectopic embryonic expression of the
transgene. These data suggest a model that is consistenthancer are expressed promiscuously in both transient and
stable transfections in many tissue culture cell lines in which with recent ®ndings showing that multiple signals from the
notochord, neural tube, and dorsal ectoderm are requiredthe chromosomal myoD gene is silent (Goldhamer et al.,
1992) and its distal enhancer methylated (this paper). These for myoD expression (Munsterberg et al., 1995; Mun-
sterberg and Lassar, 1995; Pownall et al., 1996). We proposesame constructs are regulated appropriately in transgenic
mice (Goldhamer et al., 1992, 1995; Faerman et al., 1995). that demethylation of the enhancer is regulated by one of
these signals resulting in an open chromatin conformationThe simplest hypothesis to explain this dichotomy is that
the distal myoD enhancer is regulated in part by DNA meth- that would allow the enhancer to be receptive to other sig-
nals/factors which then direct expression of the myoD gene.ylation that is established during embryogenesis and is re-
quired to repress the myoD gene in differentiated, nonmuscle Consistent with this hypothesis, we have previously shown
that the distal enhancer is DNaseI hypersensitive in myo-cell types. While epigenetic repression is maintained in tissue
culture cells at the endogenous myoD enhancer via mainte- blasts (Goldhamer et al., 1995), suggesting that the chroma-
tin at the enhancer is more open in myoblasts than in non-nance methylation, repression is not set up de novo in these
cells, allowing expression of transfected enhancer constructs muscle cell types. We can test this model by doing somite
coculture experiments using inducing tissues such as noto-that are introduced into the cells in an unmethylated state.
Consistent with this interpretation, treatment of 10T1/2 cells chord, neural tube, or dorsal ectoderm singly and in combi-
nations and assaying the methylation status of the enhancerwith the demethylating agent 5-azacytidine results in de-
methylation of the distal myoD enhancer (this study) and and transcriptional state of the myoD gene. A prediction of
this model is that demethylation of the enhancer is an ac-expression of the myoD gene (Konieczny et al., 1989). Gries-
hammer et al. (1995) have made similar observations using tive process with site, or at least region, speci®city. De-
methylation events have been identi®ed that do not requirecell lines isolated from MLC1-CAT transgenic mice. These
lines show modulated CAT activity that correlates with the DNA replication, raising the possibility of site speci®c de-
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methylation in maintenance of positionally restricted transgenemethylases (reviewed by Razin and Kafri, 1994). Jost and
expression in developing muscle. Development 121, 2245±2253.co-workers (1993, 1995) have identi®ed and partially puri-
Hannon, K., Smith, C. K., Bales, K. R., and Santerre, R. F. (1992).®ed an enzyme that actively demethylates DNA which,
Temporal and quantitative analysis of myogenic regulatory andwhile not sequence speci®c, demonstrates the possible exis-
growth factor gene expression in the developing mouse embryo.tence of enzymes such as would be required to demethylate
Dev. Biol. 151, 137±144.
the myoD core enhancer prior to myoD transcription. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease,
L. R. (1989). Site-directed mutagenesis by overlap extension using
the polymerase chain reaction. Gene 77, 51±59.
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